BNKL Insider Trading Activity and SEC Form 4 Filings
BNKL insider trading summary
No open-market insider purchases or sales of Bionik Laboratories Corp. (BNKL) have been reported on SEC Form 4 in the past 12 months.
Latest BNKL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 9, 2023 | Remi Gaston-Dreyfus | Director | Buy | $108K (180,555 @ $0.60) |
| Jun 9, 2023 | Charles Matine | Director | Buy | $108K (180,555 @ $0.60) |
| Jun 9, 2023 | Andre-Jacques Auberton-Herve | Director | Buy | $390K (650,000 @ $0.60) |
| Mar 29, 2021 | Peter Gerald Malone | Director | Buy | $0 (26,430 @ $0.00) |
| Mar 29, 2021 | Joseph R Martin | Director | Buy | $0 (26,430 @ $0.00) |
| Mar 29, 2021 | Charles Matine | Director | Buy | $0 (26,430 @ $0.00) |
| Mar 29, 2021 | Audrey Thevenon | Director | Buy | $0 (26,430 @ $0.00) |
| Mar 26, 2021 | Remi Gaston-Dreyfus | Director | Buy | $0 (135,560 @ $0.00) |
| Mar 26, 2021 | Andre-Jacques Auberton-Herve | Chairman | Buy | $0 (95,149 @ $0.00) |
| Aug 26, 2019 | Remi Gaston-Dreyfus | Director | Buy | $400K (106,358 @ $3.76) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.